ResoTher Pharma is now preparing an international phase IIb study, which is expected to begin around the turn of the year, with results due in the first half of 2028.
The longer-term goal is to secure a licensing or partnership agreement with a major international pharmaceutical company, or potentially sell the drug candidate or the company.
BREAKING